These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 6073947)

  • 1. Treatment of haemophilia B with purified Factor IX (PPSB).
    Loeliger EA; Hensen A; Mattern MJ; Veltkamp JJ; Bruning PF; Hemker HC
    Folia Med Neerl; 1967; 10(4):112-25. PubMed ID: 6073947
    [No Abstract]   [Full Text] [Related]  

  • 2. Home treatment of haemophilia and Christmas disease: five years' experience.
    Rizza CR; Spooner RJ
    Br J Haematol; 1977 Sep; 37(1):53-66. PubMed ID: 588479
    [No Abstract]   [Full Text] [Related]  

  • 3. Haemophilia.
    Biggs R
    Proc R Soc Med; 1969 Sep; 62(9):913-4. PubMed ID: 4241884
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety and efficacy of purified factor IX concentrate and antifibrinolytic agents for dental extractions in hemophilia B.
    Djulbegovic B; Marasa M; Pesto A; Kushner GM; Hadley T; Joseph G; Goldsmith G
    Am J Hematol; 1996 Feb; 51(2):168-70. PubMed ID: 8579061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Congenital deficiency of plasma thromboplastin component (PTC-factor IX): report of 25 cases from 19 unrelated families.
    Agarwal MB; Mehta BC
    J Assoc Physicians India; 1982 Jan; 30(1):17-9. PubMed ID: 6820363
    [No Abstract]   [Full Text] [Related]  

  • 6. Factor IX thrombogenicity: in vivo effects on coagulation activation and a case report of disseminated intravascular coagulation.
    Small M; Lowe GD; Douglas JT; Forbes CD; Prentice CR
    Thromb Haemost; 1982 Aug; 48(1):76-7. PubMed ID: 7135346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. The Mononine Study Group.
    White GC; Shapiro AD; Kurczynski EM; Kim HC; Bergman GE
    Thromb Haemost; 1995 May; 73(5):779-84. PubMed ID: 7482403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Coagulation factor IX inhibitor in hemophilia B].
    Lutze G; Mittler U; Presser HJ; Urbahn H
    Z Med Lab Diagn; 1990; 31(2):113-9. PubMed ID: 2343619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Preventive treatment of B type hemophilia: comparative evaluation between plasma and a concentrate of factor IX].
    Tribalto M; De Rossi G; Criscuolo D; Roseo I; Guarino S
    Clin Ter; 1975 Aug; 74(3):259-63. PubMed ID: 1227746
    [No Abstract]   [Full Text] [Related]  

  • 10. Platelets: a new target for gene therapy of haemophilia B.
    Brown MA
    Thromb Haemost; 2002 Mar; 87(3):362-3. PubMed ID: 11916064
    [No Abstract]   [Full Text] [Related]  

  • 11. Preparation and clinical use of factor IX concentrate PPSB according to Soulier.
    Haanen C; McShine RL; Kunst A
    Vox Sang; 1969 Apr; 16(4):398-411. PubMed ID: 5800593
    [No Abstract]   [Full Text] [Related]  

  • 12. Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex.
    Schimpf K; Schwarz P; Kunschak M
    Thromb Haemost; 1995 Mar; 73(3):553-5. PubMed ID: 7667845
    [No Abstract]   [Full Text] [Related]  

  • 13. [A factor IX-concentrate for the treatment of haemophilia B].
    Suomela H; Myllylä G
    Duodecim; 1971; 87(1):31-8. PubMed ID: 5539580
    [No Abstract]   [Full Text] [Related]  

  • 14. The use of a highly purified factor IX (FIX) concentrate in patients with 'haemophilia B' undergoing surgery.
    Ho PJ; Rickard KA
    Aust N Z J Med; 1995 Feb; 25(1):43-5. PubMed ID: 7786245
    [No Abstract]   [Full Text] [Related]  

  • 15. [Clinical use of factor IX concentrates].
    Nyman D
    Schweiz Med Wochenschr; 1975 Sep; 105(37):1188-90. PubMed ID: 1215901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracranial haemorrhage as initial presentation of severe haemophilia B: case report and review of Mayo Clinic Comprehensive Hemophilia Center experience.
    Rodriguez V; Schmidt KA; Slaby JA; Pruthi RK
    Haemophilia; 2005 Jan; 11(1):73-7. PubMed ID: 15660992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relation of factor VIII and IX inhibitors with ABO blood groups in 150 patients with haemophilia A and B.
    Torghabeh HM; Pourfathollah A; Shooshtari MM; Yazdi ZR
    Iran J Allergy Asthma Immunol; 2006 Mar; 5(1):33-4. PubMed ID: 17242502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of monoclonal antibody purified factor IX concentrate in previously untreated patients with hemophilia B.
    Shapiro AD; Ragni MV; Lusher JM; Culbert S; Koerper MA; Bergman GE; Hannan MM
    Thromb Haemost; 1996 Jan; 75(1):30-5. PubMed ID: 8713776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extravascular administration of factor IX: potential for replacement therapy of canine and human hemophilia B.
    Liles D; Landen CN; Monroe DM; Lindley CM; Read MS; Roberts HR; Brinkhous KM
    Thromb Haemost; 1997 May; 77(5):944-8. PubMed ID: 9184407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of factor IX inhibitor development in severe haemophilia B patients treated with only one brand of high purity plasma derived factor IX concentrate.
    Parquet A; Laurian Y; Rothschild C; Navarro R; Guérois C; Gay V; Durin A; Peynet J; Sultan Y
    Thromb Haemost; 1999 Oct; 82(4):1247-9. PubMed ID: 10544907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.